Eocene Ltd.
GLMD
Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas. The company develops pharmaceutical and device-based solutions for conditions such as liver disorders, gastrointestinal oncology, and colorectal care. Its portfolio includes Aramchol, an oral therapeutic candidate being developed for liver-related indications, as well as medical device technologies designed to support postoperative colorectal treatment. Eocene Ltd. combines research, clinical development, and product commercialization activities across its healthcare platform, with operations centered in Ramat Gan, Israel. The company serves a niche role in the biotechnology market by pursuing therapies and technologies aimed at unmet needs in gastrointestinal and adjacent medical fields.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$11M
▼ -37.1% YoY
Op. Margin
–
ROIC
-41.88%
▼ -9.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$9M
▼ -7.4% YoY
Op. Cash Flow (TTM)
-$9M
▼ -7.4% YoY
Net Debt
-$18M
Net Cash Position
Cash & Equiv.
$18M
Continue Research
Peers
Biotechnology · Pick stocks to compare with GLMD
Eocene (GLMD) in three numbers
Questions about Eocene
Is Eocene a high-quality business?
Eocene scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$18M, and its weakest is return on capital at -41.9%. The Quality tab shows every check against its target.
Does Eocene (GLMD) pay a dividend?
No. Eocene (GLMD) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GLMD
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.